Home » Newsletters » BioWorld

BioWorld

Jan. 10, 2001

View Archived Issues

InterMune Buying Alza Drug For $9M, Boosting Sales Force

SangStat Raises $12.5M Privately, Plans To Be Profitable This Year

Raven Biotech Brings In $20.6M To Develop Antibody Therapeutics

BIO Names Cohen To Head New Health Policy Position

Acorda Plans To Move Programs Along Following $33.7M Round

Other News To Note

Atrix Licenses Leuprogel Rights To Sanofi In Up-To-$60M Alliance

IntraBiotics Paying Diversa $20M In Antibacterial Deal

Adverse Events In Oxygent Patients Stops Alliance Study, Drops Stock

SADS, A Pro-Cell-Suicide Protein, Down-Regulated In Colon Cancer Tissue, Daiichi Scientists Report

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Researchers hit back after colleagues removed from ADA meeting
BioWorld
Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an...